AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9863106 — intervention group
Group type: COMPARATOR
Intervention: Positive drug Juhong Tanke Ye control group
Number of subjects: 0
Study 7930724 — intervention group
Group type: EXPERIMENTAL
Intervention: Guillain-Barré syndrome patients
Number of subjects: 42
Study 7930724 — intervention group
Group type: COMPARATOR
Intervention: Healthy blood donors
Number of subjects: 42
Study 7930724 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with positive Campylobacter serology but no neurologic disease
Number of subjects: 42
Study 3075106 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg b.i.d.
Number of subjects: 0
Study 3075106 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg b.i.d.
Number of subjects: 0
Study 3075106 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg nocte.
Number of subjects: 0
Study 3075106 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine single 20 mg bedtime dose.
Number of subjects: 0
Study 3075106 — intervention group
Group type: COMPARATOR
Intervention: Placebo.
Number of subjects: 0
Study 3075106 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (dosage not specified).
Number of subjects: 0
Study 29722482 — intervention group
Group type: EXPERIMENTAL
Intervention: ART-Def
Number of subjects: 130
Study 29722482 — intervention group
Group type: EXPERIMENTAL
Intervention: ART-40W
Number of subjects: 130
Study 29722482 — intervention group
Group type: EXPERIMENTAL
Intervention: ART-96W
Number of subjects: 130
Study 29722482 — intervention group
Group type: COMPARATOR
Intervention: HEU
Number of subjects: 130
Study 29722482 — intervention group
Group type: COMPARATOR
Intervention: HU
Number of subjects: 130
Study 26396163 — intervention group
Group type: EXPERIMENTAL
Intervention: Creative art therapy plus conventional physical therapy
Number of subjects: 118
Study 26396163 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy only
Number of subjects: 118
Study 25704621 — intervention group
Group type: COMPARATOR
Intervention: Protocol C (five-session protocol of TMJ lavage plus viscosupplementation)
Number of subjects: 30
Study 25704621 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol A (high-molecular weight hyaluronic acid)
Number of subjects: 30
Study 25704621 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol B (medium-molecular weight hyaluronic acid)
Number of subjects: 30
Study 23906869 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tranexamic acid (2.0g in 75mL of normal saline)
Number of subjects: 101
Study 23906869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 20948886 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO)
Number of subjects: 16
Study 20948886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 17625502 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg q.d. for 6 weeks then 10 mg q.d. for 6 weeks
Number of subjects: 250
Study 17625502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 17625502 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 250
Study 16645968 — intervention group
Group type: EXPERIMENTAL
Intervention: zoledronic acid (5 mg)
Number of subjects: 39
Study 14638485 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of artemether
Number of subjects: 15
Study 14638485 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of artemether
Number of subjects: 15
Study 15558877 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone
Number of subjects: 0
Study 15558877 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 0
Study 15558877 — intervention group
Group type: COMPARATOR
Intervention: Zopiclone and Zolpidem
Number of subjects: 0
Study 8864789 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal echocardiography (TEE)
Number of subjects: 44
Study 8864789 — intervention group
Group type: COMPARATOR
Intervention: Computed tomography (CT)
Number of subjects: 44
Study 1602030 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training as an adjunct to radiation therapy (34 patients)
Number of subjects: 82
Study 1602030 — intervention group
Group type: COMPARATOR
Intervention: Education and counseling along with radiation therapy (29 patients)
Number of subjects: 82
Study 6146762 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound examination at the 19th and 32nd weeks of pregnancy
Number of subjects: 510
Study 31449472 — intervention group
Group type: EXPERIMENTAL
Intervention: HHV‐6B+ BALF
Number of subjects: 553
Study 31449472 — intervention group
Group type: EXPERIMENTAL
Intervention: Antivirals within 3 days pre‐BAL
Number of subjects: 553
Study 31449472 — intervention group
Group type: COMPARATOR
Intervention: HHV‐6B‐ BALF
Number of subjects: 553
Study 28207841 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-PACK falls prevention program implementation
Number of subjects: 420
Study 26613389 — intervention group
Group type: EXPERIMENTAL
Intervention: L-methylfolate calcium (15 mg/d)
Number of subjects: 0
Study 26613389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24304196 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy (WBC) before physical exercises
Number of subjects: 96
Study 24304196 — intervention group
Group type: COMPARATOR
Intervention: Physical exercises only (Control)
Number of subjects: 96
Study 22672361 — intervention group
Group type: EXPERIMENTAL
Intervention: Full coverage acrylic stabilisation occlusal splint (Group I, n=21)
Number of subjects: 51
Study 22672361 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior device nociceptive trigeminal inhibitory (NTI) system (Group II, n=16)
Number of subjects: 51
Study 22672361 — intervention group
Group type: COMPARATOR
Intervention: Counselling for behavioural changes and self-care (Group III, n=14, Control group)
Number of subjects: 51
Study 19220676 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. imipenem-cilastatin (3 x 500 mg/day) for 7-14 days
Number of subjects: 56
Study 19220676 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic prophylaxis
Number of subjects: 56
Study 17471802 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed instruction with progressively added formal prompts
Number of subjects: 0
Study 17471802 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed instruction with one attempt
Number of subjects: 0
Study 17471802 — intervention group
Group type: EXPERIMENTAL
Intervention: Prose tutorials
Number of subjects: 0
Study 15515408 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HT3 receptor antagonist tropisetron
Number of subjects: 0
Study 10931125 — intervention group
Group type: EXPERIMENTAL
Intervention: Flow cytometry
Number of subjects: 55
Study 10931125 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine release
Number of subjects: 55
Study 10931125 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukotriene C4 release
Number of subjects: 55
Study 10931125 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin tests
Number of subjects: 55
Study 10931125 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific IgE
Number of subjects: 55
Study 10931125 — intervention group
Group type: COMPARATOR
Intervention: Flow cytometry (controls)
Number of subjects: 55
Study 9027672 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerine patches delivering 0.2 or 0.1 mg/h, applied during the first 3 days of the menstrual cycle for up to three consecutive cycles
Number of subjects: 65
Study 9027672 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerine patches
Number of subjects: 65
Study 9027672 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not explicitly detailed in the abstract)
Number of subjects: 65
Study 8319191 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent intravenous ondansetron with lorazepam and dexamethasone
Number of subjects: 80
Study 8319191 — intervention group
Group type: COMPARATOR
Intervention: Continuous-infusion metoclopramide with lorazepam, dexamethasone, and diphenhydramine
Number of subjects: 80
Study 31414842 — intervention group
Group type: EXPERIMENTAL
Intervention: Internalized stigma
Number of subjects: 242
Study 31414842 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sense of belonging
Number of subjects: 242
Study 29683030 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (anode over the ipsilesional M1 and cathode on the contralesional forehead) during 5 days of training
Number of subjects: 56
Study 29683030 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (control group)
Number of subjects: 56
Study 29683030 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (real tDCS group)
Number of subjects: 56
Study 26824379 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic nimodipine treatment
Number of subjects: 112
Study 26824379 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic nimodipine treatment
Number of subjects: 112
Study 25020273 — intervention group
Group type: COMPARATOR
Intervention: UMEC/VI 500/100 μg
Number of subjects: 103
Study 25020273 — intervention group
Group type: COMPARATOR
Intervention: UMEC/VI 125/25 μg
Number of subjects: 103
Study 25020273 — intervention group
Group type: COMPARATOR
Intervention: UMEC 500 μg
Number of subjects: 103
Study 25020273 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin
Number of subjects: 103
Study 25020273 — intervention group
Group type: COMPARATOR
Intervention: UMEC 500/100 μg
Number of subjects: 103
Study 22133208 — intervention group
Group type: EXPERIMENTAL
Intervention: BUD/FM 160/4.5 μg × 2 inhalations bid
Number of subjects: 311
Study 22133208 — intervention group
Group type: COMPARATOR
Intervention: BUD 180 μg × 2 inhalations bid
Number of subjects: 311
Study 19851815 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous repetitive sclerotherapy using polidocanol (Group 1)
Number of subjects: 94
Study 19851815 — intervention group
Group type: COMPARATOR
Intervention: Intralesional excision (extended curettage with a high-speed burr) and bone grafting (Group 2)
Number of subjects: 94
Study 19851815 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of both groups
Number of subjects: 94
Study 19851815 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment methods
Number of subjects: 94
Study 18539692 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity intervention (group A)
Number of subjects: 18280
Study 18539692 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity intervention (group B)
Number of subjects: 18280
Study 18539692 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 18280
Study 18539692 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention effect among women
Number of subjects: 18280
Study 16411785 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy interventions (including music and movement, active music listening, group chanting and singing, musical games, rhythmic training, music and sign language, and lyric analysis and rewrite activities)
Number of subjects: 34
Study 16411785 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy interventions
Number of subjects: 34
Study 12817100 — intervention group
Group type: EXPERIMENTAL
Intervention: MMN recorded at 4 days after stroke onset
Number of subjects: 8
Study 12817100 — intervention group
Group type: EXPERIMENTAL
Intervention: MMN recorded at 3 months after stroke
Number of subjects: 8
Study 12817100 — intervention group
Group type: EXPERIMENTAL
Intervention: MMN recorded between 3 and 6 months after stroke
Number of subjects: 8
Study 12817100 — intervention group
Group type: EXPERIMENTAL
Intervention: Speech-comprehension tests during follow-up
Number of subjects: 8
Study 12817100 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in duration MMN amplitude
Number of subjects: 8
Study 10974446 — intervention group
Group type: EXPERIMENTAL
Intervention: Severely anemic group (hemoglobin < 11.0 g/100 mL)
Number of subjects: 60
Study 10974446 — intervention group
Group type: COMPARATOR
Intervention: Non-anemic group (hemoglobin ≥ 11.0 g/100 mL)
Number of subjects: 60
Study 10974446 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in mean blood hemoglobin value by 1 g/100 mL
Number of subjects: 60
Study 8625547 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (IVIG) treatment
Number of subjects: 0
Study 8625547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1955231 — intervention group
Group type: EXPERIMENTAL
Intervention: Human natural leukocytic interferon (HNLI)
Number of subjects: 72
Study 1955231 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon (rIFN) alpha 2c
Number of subjects: 72
Study 6404979 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (400 mg for first 10 days, then 300-200 mg)
Number of subjects: 18
Study 6404979 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (200 mg for the whole length of therapy)
Number of subjects: 18
Study 6404979 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (both groups)
Number of subjects: 18
Study 30989563 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 186
Study 30989563 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron
Number of subjects: 186
Study 30989563 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 186
Study 29058313 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention programme
Number of subjects: 120
Study 29058313 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 27628221 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan added to combination of ACEI and BB in HFrEF patients
Number of subjects: 1147
Study 27628221 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan added to BB alone in HFpEF patients
Number of subjects: 1147
Study 27628221 — intervention group
Group type: COMPARATOR
Intervention: Olmesartan not combined with BB in HFpEF patients
Number of subjects: 1147
Study 24337725 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive depression symptoms
Number of subjects: 133
Study 24337725 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptom severity
Number of subjects: 133
Study 22927201 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral betamethasone
Number of subjects: 13
Study 22927201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 20796307 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium-oxygen
Number of subjects: 19
Study 20796307 — intervention group
Group type: COMPARATOR
Intervention: Air-oxygen
Number of subjects: 19
Study 17600286 — intervention group
Group type: EXPERIMENTAL
Intervention: peg‐IFN‐α2a 180 mcg s.c. once weekly + Ribavirin 1000‐1200 mg p.o. daily + Tα1 1.6 mg s.c. twice weekly for 24 weeks
Number of subjects: 638
Study 17600286 — intervention group
Group type: COMPARATOR
Intervention: peg‐IFN‐α2a + Ribavirin
Number of subjects: 638
Study 16227999 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variation in SEPS1 (specifically the promoter variant ‐105G ‐‐> A)
Number of subjects: 522
Study 16227999 — intervention group
Group type: EXPERIMENTAL
Intervention: Suppression of SEPS1 by short interfering RNA in macrophage cells
Number of subjects: 522
Study 16227999 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotyping of ‐105G ‐‐> A in 419 Mexican American individuals
Number of subjects: 522
Study 12137102 — intervention group
Group type: EXPERIMENTAL
Intervention: MCC (vapor compression microclimate cooling system)
Number of subjects: 8
Study 12137102 — intervention group
Group type: EXPERIMENTAL
Intervention: PIC (personal ice cooling system)
Number of subjects: 8
Study 12137102 — intervention group
Group type: EXPERIMENTAL
Intervention: TOTAL (total body cooling garment)
Number of subjects: 8
Study 12137102 — intervention group
Group type: EXPERIMENTAL
Intervention: SHIRT (hooded shirt‐only cooling garment)
Number of subjects: 8
Study 9698948 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15, 0.30, or 0.45 mg/kg racemic ketamine
Number of subjects: 8
Study 9698948 — intervention group
Group type: COMPARATOR
Intervention: Morphine 10 mg
Number of subjects: 8
Study 7869918 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil (1,200 mg/d)
Number of subjects: 29
Study 7869918 — intervention group
Group type: EXPERIMENTAL
Intervention: simvastatin (10 mg/d)
Number of subjects: 29
Study 2229837 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (IT) with birch‐pollen extract
Number of subjects: 40
Study 2229837 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 40
Study 6289661 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate
Number of subjects: 40
Study 6289661 — intervention group
Group type: COMPARATOR
Intervention: Low-dose methotrexate
Number of subjects: 40
Study 30802336 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily
Number of subjects: 48
Study 30802336 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg once daily
Number of subjects: 48
Study 30802336 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel 75 mg once daily
Number of subjects: 48
Study 30802336 — intervention group
Group type: COMPARATOR
Intervention: Control platelets
Number of subjects: 48
Study 29208004 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib
Number of subjects: 0
Study 26209855 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuraxial block
Number of subjects: 10010
Study 26209855 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative epidural analgesia
Number of subjects: 10010
Study 25103125 — intervention group
Group type: EXPERIMENTAL
Intervention: FAST‐Feedback intervention
Number of subjects: 99
Study 25103125 — intervention group
Group type: COMPARATOR
Intervention: Control group (no FAST‐Feedback)
Number of subjects: 99
Study 21909861 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocapnia group (RR adjusted to maintain PaCO(2) at 30 to 35 mmHg)
Number of subjects: 100
Study 21909861 — intervention group
Group type: COMPARATOR
Intervention: Normocapnia group (RR adjusted to maintain PaCO(2) at 35 to 45 mmHg)
Number of subjects: 100
Study 19579193 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency-powered electrothermal device (Precise™, Covidien)
Number of subjects: 82
Study 19579193 — intervention group
Group type: COMPARATOR
Intervention: Conventional thyroid surgery
Number of subjects: 82
Study 19579193 — intervention group
Group type: EXPERIMENTAL
Intervention: Device-supported thyroid surgery (Precise™ and Focus™)
Number of subjects: 82
Study 19579193 — intervention group
Group type: COMPARATOR
Intervention: Classic tie-and-knotting procedure
Number of subjects: 82
Study 19579193 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative morbidity
Number of subjects: 82
Study 17557349 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan succinate (50mg)
Number of subjects: 102
Study 17557349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 16487712 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (15 mg/kg)
Number of subjects: 29
Study 16487712 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 29
Study 12909471 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at 20 parts per million
Number of subjects: 36
Study 12909471 — intervention group
Group type: COMPARATOR
Intervention: Control group (historical subjects)
Number of subjects: 36
Study 11083483 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea
Number of subjects: 64
Study 11083483 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea
Number of subjects: 64
Study 11083483 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea polyphenol isolate
Number of subjects: 64
Study 11083483 — intervention group
Group type: COMPARATOR
Intervention: Mineral water
Number of subjects: 64
Study 11083483 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant beta-carotene
Number of subjects: 64
Study 11083483 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant alpha-tocopherol
Number of subjects: 64
Study 8767378 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmediastinal dissection
Number of subjects: 32
Study 8767378 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthoracic en bloc resection
Number of subjects: 32
Study 8767378 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 8767378 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 32
Study 1997887 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy and chloroethylnitrosoureas (methyl‐CCNU, 100‐120 mg/m2, or ACNU 80‐100 mg/m2, every 6‐8 weeks)
Number of subjects: 100
Study 1997887 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy and a combination of chloroethylnitrosoureas and tegafur (300 mg/m2, daily)
Number of subjects: 100
Study 1997887 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 100
Study 6438682 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (N = 20) underwent 4 days of tobacco deprivation
Number of subjects: 27
Study 28722815 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg morphine
Number of subjects: 41
Study 28722815 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 mL Aqua)
Number of subjects: 41
Study 28722815 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.2 mg/mL)
Number of subjects: 41
Study 28722815 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocebo
Number of subjects: 41
Study 29228918 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine-based ART
Number of subjects: 284
Study 29228918 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz-based ART
Number of subjects: 284
Study 25230071 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Wheelchair (MWC)
Number of subjects: 59
Study 25230071 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-Wheeled Walker (WW)
Number of subjects: 59
Study 25230071 — intervention group
Group type: COMPARATOR
Intervention: Powered Wheelchair (PWC)
Number of subjects: 59
Study 24899329 — intervention group
Group type: EXPERIMENTAL
Intervention: Kennedy Class III classification
Number of subjects: 194
Study 24899329 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender and employment status comparison
Number of subjects: 194